Advertisement

Fecal Microbiota Transplantation: Beyond Clostridium difficile

  • Braden Millan
  • Michael Laffin
  • Karen MadsenEmail author
Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Intra-abdominal Infections, Hepatitis, and Gastroenteritis

Abstract

Purpose of Review

Fecal microbiota transplantation (FMT) has been established as standard of care in the treatment of antibiotic refractory Clostridium difficile infection (RCDI). This review examines the current evidence that exists to support the use of FMT in the treatment of human disease beyond C. difficile infection.

Recent Findings

Beneficial effects of FMT have been described in case series or small prospective trials on a wide spectrum of conditions, including inflammatory bowel disease, functional gastrointestinal disorders, non-alcoholic steatohepatitis, alcoholic hepatitis, hepatic encephalopathy, and neuropsychiatric conditions, and in limiting antibiotic-resistant bacterial infections. Each of these proposed indications for FMT is associated with an underlying dysbiosis of the gastrointestinal microbiota and generally a clinical response is linked with a restoration of the gut microbiota.

Summary

The potential of fecal microbial transplantation to alter disease course shows promise but further large-scale studies are necessary to understand limitations as well as how best to utilize this therapy.

Keywords

Fecal microbiota transplantation Antibiotic resistance Inflammatory bowel disease Gastrointestinal Microbiota 

Notes

Compliance with Ethical Standards

Conflict of Interest

Braden Millan, Michael Laffin, and Karen Madsen declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Forslund K, Sunagawa S, Kultima JR, Mende DR, Arumugam M, Typas A, et al. Country-specific antibiotic use practices impact the human gut resistome. Genome Res. 2013;23(7):1163–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bilinski J, Grzesiowski P, Sorensen N, Madry K, Muszynski J, Robak K, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017. doi: 10.1093/cid/cix252.
  3. 3.
    • Millan B, Park H, Hotte N, Mathieu O, Burguiere P, Tompkins TA, et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2016;62(12):1479–86. Antibiotic resistance is a growing problem, and the potential of FMT to modulate antibiotic-resistant microbial populations may play a crucial role in combating this issue. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jouhten H, Mattila E, Arkkila P, Satokari R. Reduction of antibiotic resistance genes in intestinal microbiota of patients with recurrent Clostridium difficile infection after fecal microbiota transplantation. Clin Infect Dis. 2016;63(5):710–1.CrossRefPubMedGoogle Scholar
  5. 5.
    Mahieu R, Cassisa V, Hilliquin D, Coron N, Pailhories H, Kempf M, et al. Impact of faecal microbiota transplantation on mouse digestive colonization with two extensively resistant bacteria. J Inf Secur. 2017;75(1):75–7.Google Scholar
  6. 6.
    Sohn KM, Cheon S, Kim YS. Can fecal microbiota transplantation (FMT) eradicate fecal colonization with vancomycin-resistant enterococci (VRE)? Infect Control Hosp Epidemiol. 2016;37(12):1519–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Stalenhoef JE, Terveer EM, Knetsch CW, Van't Hof PJ, Vlasveld IN, Keller JJ, et al. Fecal microbiota transfer for multidrug-resistant gram-negatives: a clinical success combined with microbiological failure. Open Forum Infect Dis. 2017;4(2):ofx047.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    •• Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017. doi: 10.1093/ecco-jcc/jjx063. This review offers the most complete up-to-date overview of the evidence regarding FMT for IBD. This is important given the apparent effectiveness of FMT in the induction of UC remission and its potential in CD and pouchitis.
  9. 9.
    Keshteli AH, Millan B, Madsen KL. Pretreatment with antibiotics may enhance the efficacy of fecal microbiota transplantation in ulcerative colitis: a meta-analysis. Mucosal Immunol. 2017;10(2):565–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102–9. e6. CrossRefPubMedGoogle Scholar
  11. 11.
    Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn’s disease. Inflamm Bowel Dis. 2016;22(9):2182–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Cui B, Li P, Xu L, Peng Z, Xiang J, He Z, et al. Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes. 2016;7(4):323–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109(11):1831–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Tian H, Ge X, Nie Y, Yang L, Ding C, McFarland LV, et al. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PLoS One. 2017;12(2):e0171308.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ge X, Ding C, Gong J, Tian H, Wei Y, Chen Q, et al. Short-term efficacy on fecal microbiota transplantation combined with soluble dietary fiber and probiotics in the treatment of slow transit constipation. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(12):1355–9.PubMedGoogle Scholar
  16. 16.
    Gu L, Ding C, Tian H, Yang B, Zhang X, Hua Y, et al. Serial frozen fecal microbiota transplantation in the treatment of chronic intestinal pseudo-obstruction: a preliminary study. J Neurogastroenterol Motil. 2017;23(2):289–97.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wang J, Gu J, Wang Y, Lin K, Liu S, Lu H, et al. 16S rDNA gene sequencing analysis in functional dyspepsia treated with fecal microbiota transplantation. J Pediatr Gastroenterol Nutr. 2017;64(3):e80–e2.CrossRefPubMedGoogle Scholar
  18. 18.
    Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33(3):128–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7(1):1529.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Philips CA, Pande A, Shasthry SM, Jamwal KD, Khillan V, Chandel SS, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017;15(4):600–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Bajaj JS, Kassam Z, Fagan A, Gavis E, Liu E, Cox J, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Riva A, Smith M, Raylor-Robinson S, Gillevet P. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017 doi:  10.1002/hep.29306.
  22. 22.
    Kao D, Roach B, Park H, Hotte N, Madsen K, Bain V, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology. 2016;63(1):339–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Li M, Liang P, Li Z, Wang Y, Zhang G, Gao H, et al. Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Front Microbiol. 2015;6:692.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Wei Y, Yang J, Wang J, Yang Y, Huang J, Gong H, et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care. 2016;20(1):332.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cui M, Xiao H, Li Y, Zhou L, Zhao S, Luo D, et al. Faecal microbiota transplantation protects against radiation-induced toxicity. EMBO Mol Med. 2017;9(4):448–61.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics. 2014;133(5):872–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    •• Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med. 2017;167(1):34–39. doi:  10.7326/M16-2810. Important methodological components of FMT are not standardized or detailed in many current papers utilizing the therapy, a problem that is assessed in this review. The widespread use and success of FMT will rely upon rigorous reporting of the technical aspects involved in FMT.
  29. 29.
    Kelly CR, Kim AM, Laine L, Wu GD. The AGA’s Fecal Microbiota Transplantation National Registry: an important step toward understanding risks and benefits of microbiota therapeutics. Gastroenterology. 2017 Mar;152(4):681–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Cumming School of MedicineUniversity of CalgaryCalgaryCanada
  2. 2.Department of Medicine, CEGIIR: Center of Excellence for Gastrointestinal Inflammation and Immunity Research, 7-142 Katz Group CenterUniversity of AlbertaEdmontonCanada

Personalised recommendations